» Articles » PMID: 17103489

Viral Infections As Potential Triggers of Type 1 Diabetes

Overview
Specialty Endocrinology
Date 2006 Nov 15
PMID 17103489
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

During the last decades, the incidence of type 1 diabetes (T1D) has increased significantly, reaching percentages of 3% annually worldwide. This increase suggests that besides genetical factors environmental perturbations (including viral infections) are also involved in the pathogenesis of T1D. T1D has been associated with viral infections including enteroviruses, rubella, mumps, rotavirus, parvovirus and cytomegalovirus (CMV). Although correlations between clinical presentation with T1D and the occurrence of a viral infection that precedes the development of overt disease have been recognized, causalities between viruses and the diabetogenic process are still elusive and difficult to prove in humans. The use of experimental animal models is therefore indispensable, and indeed more insight in the mechanism by which viruses can modulate diabetogenesis has been provided by studies in rodent models for T1D such as the biobreeding (BB) rat, nonobese diabetic (NOD) mouse or specific transgenic mouse strains. Data from experimental animals as well as in vitro studies indicate that various viruses are clearly able to modulate the development of T1D via different mechanisms, including direct beta-cell lysis, bystander activation of autoreactive T cells, loss of regulatory T cells and molecular mimicry. Data obtained in rodents and in vitro systems have improved our insight in the possible role of viral infections in the pathogenesis of human T1D. Future studies will hopefully reveal which human viruses are causally involved in the induction of T1D and this knowledge may provide directions on how to deal with viral infections in diabetes-susceptible individuals in order to delay or even prevent the diabetogenic process.

Citing Articles

The relationship between SARS-CoV-2 infection and type 1 diabetes mellitus.

Debuysschere C, Nekoua M, Alidjinou E, Hober D Nat Rev Endocrinol. 2024; 20(10):588-599.

PMID: 38890459 DOI: 10.1038/s41574-024-01004-9.


Progress in experimental models to investigate the in vivo and in vitro antidiabetic activity of drugs.

Janapati Y, Junapudi S Animal Model Exp Med. 2024; 7(3):297-309.

PMID: 38837635 PMC: 11228097. DOI: 10.1002/ame2.12442.


Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review.

Xie X, Wu C, Hao Y, Wang T, Yang Y, Cai P Front Endocrinol (Lausanne). 2024; 14:1301093.

PMID: 38179301 PMC: 10766371. DOI: 10.3389/fendo.2023.1301093.


Clinical and biological heterogeneity of multisystem inflammatory syndrome in adults following SARS-CoV-2 infection: a case series.

Barth K, Spottiswoode N, Hurabielle C, Subbaraj L, Calfee C, Matthay M Front Med (Lausanne). 2023; 10:1187420.

PMID: 37484839 PMC: 10357379. DOI: 10.3389/fmed.2023.1187420.


Understanding Insulin in the Age of Precision Medicine and Big Data: Under-Explored Nature of Genomics.

Cook T, Wilstermann A, Mitchell J, Arnold N, Rajasekaran S, Bupp C Biomolecules. 2023; 13(2).

PMID: 36830626 PMC: 9953665. DOI: 10.3390/biom13020257.